Gender-specific decrease in NUDR and 5-HT$_{1A}$ receptor proteins in the prefrontal cortex of subjects with major depressive disorder

Bernadeta Szewczyk$^{1,2}$, Paul R. Albert$^3$, Ariel M. Burns$^3$, Margaret Czesak$^3$, James C. Overholser$^4$, George J. Jurjus$^5$, Herbert Y. Meltzer$^6$, Lisa C. Konick$^5$, Lesa Dieter$^5$, Nicole Herbst$^5$, Warren May$^7$, Grazyna Rajkowska$^1$, Craig A. Stockmeier$^{1,5}$ and Mark C. Austin$^1$

$^1$Department of Psychiatry and Human Behavior, University of Mississippi Medical Center, Jackson, MS, USA
$^2$Department of Neurobiology, Institute of Pharmacology, Polish Academy of Science, Krakow, Poland
$^3$Ottawa Health Research Institute (Neuroscience), University of Ottawa, Canada
$^4$Department of Psychology, Case Western Reserve University, Cleveland, OH, USA
$^5$Department of Psychiatry, Case Western Reserve University, Cleveland, OH, USA
$^6$Department of Psychiatry, Psychiatric Hospital at Vanderbilt, Nashville, TN, USA
$^7$Department of Preventive Medicine, University of Mississippi Medical Center, Jackson, MS, USA

Abstract

A variety of studies have documented alterations in 5-HT$_{1A}$ receptor binding sites in the brain of subjects with major depressive disorder (MDD). The recently identified transcription factor, nuclear deformed epidermal autoregulatory factor (NUDR/Deaf-1) has been shown to function as a transcriptional modulator of the human 5-HT$_{1A}$ receptor gene. The present study was undertaken to document the regional and cellular localization of NUDR in the human prefrontal cortex and to examine the levels of NUDR and 5-HT$_{1A}$ receptor protein in prefrontal cortex of female and male depressed and control subjects. NUDR immunoreactivity was present in neurons and glia across cortical layers and was co-localized with 5-HT$_{1A}$ receptor immunoreactive neurons. NUDR immunoreactivity as measured by Western blot was significantly decreased in the prefrontal cortex of female depressed subjects (42%, $p=0.02$) and unchanged in male depressed subjects relative to gender-matched control subjects. Similarly, 5-HT$_{1A}$ receptor protein level was significantly reduced in the prefrontal cortex of female depressed subjects (46%, $p=0.03$) and unchanged in male depressed subjects compared to gender-matched control subjects. Reduced protein expression of NUDR in the prefrontal cortex of female subjects with MDD may reflect a functional alteration in this transcription factor, which may contribute to the decrease in 5-HT$_{1A}$ receptors observed in the same female subjects with MDD. In addition, the gender-specific alterations in cortical NUDR and 5-HT$_{1A}$ receptor proteins could represent an underlying biological mechanism associated with the higher incidence of depression in women.

Received 18 February 2008; Reviewed 20 March 2008; Revised 4 April 2008; Accepted 4 May 2008; First published online 19 June 2008

Key words: Female, major depression, prefrontal cortex, transcription factor, 5-HT$_{1A}$ receptors.

Introduction

Clinical and human post-mortem studies have provided evidence supporting the hypothesis that serotonin neurotransmission is reduced in major depressive disorder (MDD), with specific alterations noted in serotonin receptor subtypes. The 5-HT$_{1A}$ receptor is important since these receptors may function as somatodendritic autoreceptors on serotonin neurons and thereby regulate the activity of dorsal raphe neurons. In addition, 5-HT$_{1A}$ receptors are also located post-synaptically on neurons and glia in the prefrontal cortex (PFC) and limbic structures (Hoyer et al., 2002; Riad et al., 2000; Sotelo et al., 1990). Moreover, serotonin-selective reuptake inhibitors (SSRIs) are
believed to exert at least part of their antidepressant effects by a desensitization of 5-HT$_{1A}$ receptors. It is also important to note that previous studies have reported that oestrogen reduces 5-HT$_{1A}$ autoreceptor binding sites, mRNA levels and basal and stimulated $[^{35}S]$GTP-γ-S binding in the dorsal raphe nucleus and decreased post-synaptic 5-HT$_{1A}$ receptor-binding sites in the hypothalamus (Lu and Bethea, 2002). Thus, oestrogen treatment appears to modulate 5-HT$_{1A}$ receptor expression in distinct brain regions.

In vivo imaging studies have reported alterations in 5-HT$_{1A}$ receptors in the brain of depressed patients. For example, Sargent et al. (2000) used positron emission tomography (PET) with the selective 5-HT$_{1A}$ receptor antagonist, $[^{18}F]$WAY-100635, and reported decreased 5-HT$_{1A}$ receptor binding potential in the frontal, temporal and limbic cortices of male subjects with MDD. Bhagwagar et al. (2004) noted the decrease in 5-HT$_{1A}$ binding potential throughout the cortex and limbic structures persisted in MDD despite clinical remission. Meltzer and colleagues (2004) saw no changes in 5-HT$_{1A}$ receptor binding potential in PFC but noted a decrease in 5-HT$_{1A}$ receptor binding in the dorsal raphe nuclei of late-life depressives.

Although some studies of human post-mortem tissue have also reported alterations in 5-HT$_{1A}$ receptors in specific brain regions in suicide or subjects with MDD, the results have not been consistent. Stockmeier and colleagues (1998) reported elevated radioligand binding to presynaptic 5-HT$_{1A}$ autoreceptors in specific subnuclei of the midbrain dorsal raphe nuclei of suicide victims with MDD. However, Arango et al. (2001) subsequently reported a decrease in 5-HT$_{1A}$ receptor ‘binding capacity’ in the dorsal raphe of depressed suicide victims relative to controls. Yet a recent report from these investigators contradicts their earlier finding and reveals an increase in 5-HT$_{1A}$ autoreceptor binding sites in the rostral dorsal raphe of suicide victims (Boldrini et al., 2008) which is consistent with the original Stockmeier et al. (1998) report. Several other groups have measured post-synaptic 5-HT$_{1A}$ receptors in the PFC of depressed suicide victims but again with disparate results. Matsubara et al. (1991) reported an increase in 5-HT$_{1A}$ receptors in Brodmann area (BA) 8 and 9 of the PFC of so-called non-violent suicide victims that were not psychiatrically characterized. Moreover, Arango et al. (1995) reported elevated binding to 5-HT$_{1A}$ receptor binding sites in the ventrolateral PFC only of uncharacterized suicide victims. In contrast, Lopez-Figueroa et al. (2004) found decreased 5-HT$_{1A}$ receptor mRNA levels in the dorsolateral PFC in MDD and Hsiung et al. (2003) reported reductions in 5-HT$_{1A}$ receptor signalling in the occipital cortex of depressed suicide victims. Stockmeier et al. (1997), however, found no changes in binding to 5-HT$_{1A}$ receptors in BA 10 of the PFC of suicide victims with MDD. Although these reports contain conflicting results, they suggest that alterations in 5-HT$_{1A}$ receptors do exist in the brain of depressed subjects.

Recent data reveal several single nucleotide polymorphisms (SNPs) of the 5-HT$_{1A}$ receptor gene, although not all these mutations have a high frequency in the general population or an association with a psychiatric illness (Arias et al., 2002; Erdmann et al., 1995; Kawashishi et al., 1998; Wu and Comings, 1999). Recently, a novel C(-1019)G polymorphism in the 5-HT$_{1A}$ receptor gene promoter was identified (Lemonde et al., 2003). This polymorphism is prevalent in the normal population (Wu and Comings, 1999) and the G(-1019) allele is two-fold more frequent in subjects with MDD and four-fold enriched in suicide victims relative to matched control subjects (Lemonde et al., 2003). Recently, a nuclear protein complex, nuclear deformed epidermal autoregulatory factor-1 (Def-1) or the human homolog, NUDR, was identified that binds to the C(-1019) allele of the 5-HT$_{1A}$ receptor and represses the transcription activity of the C(-1019) allele of the 5-HT$_{1A}$ receptor promoter (Albert and Lemonde, 2004; Lemonde et al., 2003). This binding does not occur with the G(-1019) allele of the 5-HT$_{1A}$ receptor promoter. In vitro cell-culture studies showed that this transcriptional repression results in a significant decrease in endogenous 5-HT$_{1A}$ receptor mRNA, protein and binding sites (Lemonde et al., 2003). Immunocytochemical studies revealed that NUDR is localized to neurons in the rodent raphe nuclei, hippocampus and the frontal cortex and is co-localized with 5-HT$_{1A}$ receptors in these brain regions (Lemonde et al., 2003). However, recent data in non-serotonergic cells indicated that NUDR functions as an enhancer rather than repressor of 5-HT$_{1A}$ receptors (Czesak et al., 2006). These data suggest that cell-specific regulation by NUDR may underlie region-specific alterations in the expression of 5-HT$_{1A}$ receptors.

Given the transcriptional regulatory role of NUDR on 5-HT$_{1A}$ receptors, the co-localization of NUDR and 5-HT$_{1A}$ receptors in neurons, the interaction of NUDR with the C(-1019) polymorphism of the 5-HT$_{1A}$ receptor gene, and the substantial evidence of alterations in 5-HT$_{1A}$ receptors in depressed subjects, we sought to determine whether alterations in NUDR may exist in the brain of depressed individuals, whether this may be associated with alterations in 5-HT$_{1A}$ receptors, and whether gender-specific...
alterations in these two proteins may exist in subjects with depression. The present study was designed to quantify NUDR and 5-HT<sub>1A</sub> receptor protein levels in BA 10 of the PFC of female and male subjects diagnosed with MDD and in psychiatrically normal control subjects matched for gender.

Methods

Subjects

All procedures in our study were approved by the Institutional Review Board of the University of Mississippi Medical Center and University Hospitals of Cleveland. Human brain specimens were obtained in the course of routine autopsies conducted at the Cuyahoga County Coroner’s Office, Cleveland, OH, after obtaining written consent from the legally defined next-of-kin. Blood and urine samples from all subjects were examined by the coroner’s office for psychotropic medications and substances of abuse. Subjects included 13 female and 11 male subjects diagnosed with MDD, and one male subject with dysthymia. The 13 female and 12 male control subjects never met criteria for an Axis I illness and had no history of a neurological disorder. Each depressed subject was matched with a control subject for gender and as closely as possible for age and post-mortem interval (PMI). Some of the pairs were also matched for race. The demographics for each subject are summarized in Table 1.

Retrospective, informant-based psychiatric assessments were performed for all depressed and control subjects as previously described (Stockmeier et al., 2004). About 3 months after the death of the subjects, a trained interviewer administered the Schedule for Affective Disorders and Schizophrenia: Lifetime Version (SADS-L; Spitzer and Endicott, 1978) to knowledgeable next-of-kin of 18 of the depressed subjects, as previously described (Stockmeier et al., 1997). The Structured Clinical Interview for DSM-IV Psychiatric Disorders (SCID; First et al., 1996) was administered to next-of-kin of the seven remaining depressed subjects. Axis I psychopathology was independently assessed by a clinical psychologist and psychiatrist and consensus diagnosis was reached in conference using information from the interview, previous hospitalizations and doctors’ records, and the coroner’s office. Responses from the subjects evaluated with the SADS-L were also recorded in the SCID, and regardless of the structured diagnostic interview used, all subjects met DSM-IV criteria for MDD (APA, 1994). Twenty-three subjects met DSM-IV criteria for a major depressive episode within the last month of life and MDD was in partial remission for one subject.

All 13 female depressed subjects met DSM-IV criteria for an Axis I diagnosis of MDD. Twelve female subjects met criteria for MDD within the last month of life and one female subject was in partial remission during the last month. Eleven female subjects had multiple depressive episodes during their life and two female subjects had a single episode. Alcohol dependence in one female subject and alcohol abuse in another were in remission at the time of death. Among the 13 female depressed subjects, 11 had a prescription for an antidepressant medication at the time of death, although post-mortem toxicology screening revealed the presence of only diazepam in one subject. The mean (±S.E.M.) age of onset of depression was 32.0 ± 4.2 yr and the average duration of illness was 23.7 ± 4.3 yr.

Eleven male depressed subjects met DSM-IV criteria for an Axis I diagnosis of MDD, and all 11 met this criteria for MDD in the last month of life. One depressed male subject met clinical criteria for dysthymia. Nine male subjects had multiple depressive episodes during their life and two male subjects had a single episode. Two male subjects had a history of alcohol abuse and one of benzodiazepine abuse, although these disorders were in remission at the time of death. Among the 12 depressed male subjects, eight had a prescription for an antidepressant medication at the time of death, although post-mortem toxicology screening revealed only the presence of temazepam. The mean (±S.E.M.) age of onset of depression was 45.3 ± 4.8 yr and the average duration of illness was 9.9 ± 3.1 yr.

Tissue sampling

The study was carried out on blocks of tissue which were dissected approximately 1–2 cm from the frontal pole of the right hemisphere. The tissue blocks consisted of BA 10, however, some portions of the blocks also contained cytoarchitectonic features of adjacent areas BA 11, 47 or 9. In order to ensure that sections or tissue punches were collected consistently from BA 10, two 30-μm-thick sections were cut from each block and stained for Nissl prior to sampling. Microscopic examination distinguished BA 10 from the adjacent prefrontal areas by the presence of a very broad, densely packed layer IV, the large size of neurons in layers III, V and VI and by the relatively similar width of layers III and V (Rajkowska and Goldman, 1995).
Immunohistochemistry

Immunohistochemistry was used to examine the expression and laminar distribution of NUDR in the human PFC of normal control subjects. Frozen 30-μm sections from PFC (BA 10) were fixed in 4% paraformaldehyde (in 0.05 M PBS) for 1 h at room temperature, preincubated in 5% normal horse serum in PBS for 30 min and then incubated for 24 h at 4°C in the same solution containing rabbit anti-NUDR polyclonal antibody (1:50, Lemonde et al., 2003). Sections were washed in PBS and incubated for 4 h at room temperature in biotinylated horse anti-rabbit IgG (1:200; Vector Laboratories, Burlingame, CA, USA) in PBS buffer. After incubation, the sections were processed using the Vectastain ABC immunoperoxidase kit (Vector) for 24 h at 4°C. Antibody distribution was visualized using 3,3’-diaminobenzidine tetrahydrochloride (DAB; 0.05%, Sigma, St Louis, MO, USA).

Immunofluorescence

Immunofluorescence was used to examine the cellular expression of NUDR and co-localization with 5-HT1A receptor in the human PFC. Frozen 20-μm

Table 1. Demographic characteristic of the subjects

<table>
<thead>
<tr>
<th>Pair</th>
<th>Control</th>
<th>MDD</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sex/race/age (yr)</td>
<td>PMI (h)</td>
</tr>
<tr>
<td>1</td>
<td>F/B/58</td>
<td>12</td>
</tr>
<tr>
<td>2</td>
<td>F/B/67</td>
<td>16</td>
</tr>
<tr>
<td>3</td>
<td>F/B/51</td>
<td>22</td>
</tr>
<tr>
<td>4</td>
<td>F/W/50</td>
<td>27</td>
</tr>
<tr>
<td>5</td>
<td>F/W/83</td>
<td>25</td>
</tr>
<tr>
<td>6</td>
<td>F/W/65</td>
<td>26</td>
</tr>
<tr>
<td>7</td>
<td>F/W/38</td>
<td>11</td>
</tr>
<tr>
<td>8</td>
<td>F/B/80</td>
<td>21</td>
</tr>
<tr>
<td>9</td>
<td>F/W/46</td>
<td>24</td>
</tr>
<tr>
<td>10</td>
<td>F/W/23</td>
<td>11</td>
</tr>
<tr>
<td>11</td>
<td>F/W/78</td>
<td>11</td>
</tr>
<tr>
<td>12</td>
<td>F/W/49</td>
<td>29</td>
</tr>
<tr>
<td>13</td>
<td>F/W/44</td>
<td>32</td>
</tr>
<tr>
<td>14</td>
<td>M/W/71</td>
<td>24</td>
</tr>
<tr>
<td>15</td>
<td>M/W/44</td>
<td>6</td>
</tr>
<tr>
<td>16</td>
<td>M/W/59</td>
<td>6</td>
</tr>
<tr>
<td>17</td>
<td>M/W/27</td>
<td>17</td>
</tr>
<tr>
<td>18</td>
<td>M/W/73</td>
<td>22</td>
</tr>
<tr>
<td>19</td>
<td>M/W/58</td>
<td>21</td>
</tr>
<tr>
<td>20</td>
<td>M/W/47</td>
<td>17</td>
</tr>
<tr>
<td>21</td>
<td>M/W/47</td>
<td>25</td>
</tr>
<tr>
<td>22</td>
<td>M/B/53</td>
<td>23</td>
</tr>
<tr>
<td>23</td>
<td>M/W/57</td>
<td>10</td>
</tr>
<tr>
<td>24</td>
<td>M/W/82</td>
<td>16</td>
</tr>
<tr>
<td>25</td>
<td>M/B/27</td>
<td>11</td>
</tr>
</tbody>
</table>

MDD, Major depressive disorder; F, female; M, male; W, white; B, black; PMI, post-mortem interval in hours; Episodes (S, single; M, multiple); HCD, hypertensive cardiac disease; CSHD, coronary sclerotic heart disease; MVA, motor vehicle accident; ACD, atherosclerotic cardiovascular disease; CO, carbon monoxide; SIGSW, self-inflicted gunshot wound.

Female controls (mean ± S.E.M) [age (56 ± 5 yr), PMI (20 ± 2 h), pH (6.5 ± 0.06)]. Female MDD (mean ± S.E.M) [age (56 ± 5 yr), PMI (21 ± 1 h), pH (6.6 ± 0.06)]. Onset of depression (32.0 ± 4.2 yr); duration of depression (23.7 ± 4.3 yr).

Male controls (mean ± S.E.M) [age (54 ± 5 yr), PMI (16.5 ± 2 h), pH (6.7 ± 0.06)]. Male MDD (mean ± S.E.M) [age (55 ± 4.5 yr), PMI (17 ± 2 h), pH (6.7 ± 0.07)]. Onset of depression (45.3 ± 4.8 yr); duration of depression (9.9 ± 3.0 yr).

*Subject diagnosed as dysthymia alone (no MDD).
sections from PFC (BA 10) were subjected to a double fluorescent immunolabelling procedure to detect in individual sections simultaneously NUDR and the neuronal marker – neuronal nuclei (NeuN), NUDR and astrocytic marker – glial fibrillary acidic protein (GFAP), NUDR and 5-HT\textsubscript{1A} receptor. Each section was incubated overnight with rabbit anti-NUDR polyclonal antibody (1:50) and a mouse anti-GFAP monoclonal antibody (1:1000; Chemicon, Temecula, CA, USA), a mouse anti-NeuN monoclonal antibody (1:1000; Chemicon) or a mouse anti-5-HT\textsubscript{1A} polyclonal antibody (1:100, Affinity Bio-reagents, Golden, CO, USA) respectively. After washes in TBS, sections were incubated for 90 min with a mixture of a goat anti-mouse antibody conjugated with the fluorochrome Cy5 (1:200; Jackson Immunochemical, Bar Harbor, ME, USA) and a goat anti-rabbit antibody conjugated to fluorochrome Cy2 (1:200; Jackson Immunochemical) and washed again before coverslipping. Omission of the primary or the secondary antibody resulted in the absence of immunostaining. The cellular localization of immunofluorescence was analysed using a Nikon confocal microscope.

**Western blot**

Immunolabelling of NUDR and the 5-HT\textsubscript{1A} receptor were determined in tissue punches from PFC (BA 10). Equal volumes of protein samples containing mostly membrane and nuclear fraction (30 \(\mu\)g of protein) were resolved on 12.5% SDD-PAGE and blotted on nitrocellulose membrane. The blots were incubated overnight at 4°C with affinity-purified primary rabbit anti-NUDR polyclonal antibody that was generated to an amino-terminal peptide from NUDR (1:5000, Lemonde et al., 2003) and with rabbit anti-5-HT\textsubscript{1A} receptor polyclonal antibody (1:2000; Aviva System Biology, San Diego, CA, USA). Antibody specificity experiments revealed that preincubation of the primary 5-HT\textsubscript{1A} receptor antibody with a specific 5-HT\textsubscript{1A} peptide (Aviva System Biology), and preincubation of the primary NUDR antibody with a specific NUDR peptide completely blocked immunoreactivity. As a control for transfer and sample loading, anti-\(\beta\)-actin monoclonal antibody was used (1:5000, Chemicon). Immunoreactivity of NUDR and 5-HT\textsubscript{1A} receptor was investigated in pairs of depressed and control subjects matched for age, gender and PMI. Each subject pair was immunoblotted in duplicate. The relationship between optical density values and the concentrations of NUDR and 5-HT\textsubscript{1A} receptor immunoreactivities respectively was determined by loading increasing concentrations of sample onto gels and immunoblotting with anti-NUDR or anti-5HT\textsubscript{1A} receptor antibody. Relative optical density values of immunoreactive bands were measured and presented as a function of protein concentration. The relationship between optical density and protein concentrations was linear (Figure 1).

Relative optical density of NUDR and 5-HT\textsubscript{1A} bands were analysed using imaging software (MCID Elite 7.0; Imaging Research, St Catherine’s, ON, Canada) and normalized by the optical density of the corresponding \(\beta\)-actin band. The anti-NUDR and anti-5-HT\textsubscript{1A} receptor antibody-detected bands on the gel corresponded to a molecular weight of 59 kDa and 56 kDa respectively.

**Genotype analysis**

Genomic DNA extracted was from brain samples of the 13 female and 12 male depressed subjects and 13 female and 12 male matched controls used for protein study. DNA was isolated from the brain tissue using the QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA). The protocol was followed exactly, starting with 25 mg frozen tissue and eluting the DNA with 50 \(\mu\)l buffer AE. All DNA samples were stored at \(-20^\circ\text{C}\). Genotyping of all DNA samples for the 5-HT\textsubscript{1A} C(-1019)G SNP was performed by Q-PCR using TaqMan SNP Genotyping Assay no. C\textsubscript{1190466}_10 (Applied Biosystems, Foster City, CA, USA). The
genotyping reaction was carried out in a 10 µl final volume of reaction mixture containing: 1 µl DNA, 5 µl TaqMan Universal PCR Master Mix, 0.5 µl of the appropriate 20x TaqMan SNP Genotyping Assay Mix, and 3.5 µl of nuclease-free water. In addition, duplicate, no template controls (nuclease-free water instead of DNA) were run in order to detect contamination of the reaction mixture. The Q-PCR run was performed using the Rotor-Gene 3000 Cycler (Corbett Research, Sydney, Australia). The thermocycler programme was as follows: 95 °C for 10 min (enzyme activation step); 40 cycles: 92 °C for 15 s, 60 °C for 1 min; hold at 25 °C. Genotypes were then determined using the Allelic Discrimination function of the Rotor-Gene software (version 6). The 5-HT₁A TaqMan assay was validated by genotyping 20 samples previously analysed by manual sequencing (Lemonde et al., 2003).

Statistical analysis

Data were analysed using a matched-pairs design. Each subject was measured at least twice so that there are two sources of potentially correlated observations, replicates within subjects and subjects within pairs. That is, data are considered multilevel with subjects representing the first level and pairs representing the second level. Statistical tests were performed separately for male and female groups. A maximum-likelihood mixed-models test was used to estimate parameters of the models, assuming pairs and subjects within pairs were random components (SAS; Little et al., 1996). As a first step, unadjusted models were fit to compare depressives vs. controls without adjusting for potential confounders. Gender-specific adjusted models included the main effect for comparing depressives vs. controls and covariates for age, PMI, pH and cause of case death (suicide vs. non-suicide). Interactions between the main effect, depressives vs. controls, and each of the potentially confounding covariates was investigated and dropped from the model if it was not statistically significant. Results for the depressed and control groups are reported as mean±s.e. based on the mixed model. Results for main effects are considered significant if \( p < 0.05 \).

Genotype frequencies between depressed and control subjects were compared by \( \chi^2 \) analysis with two-tailed \( p \) values; allele frequencies were compared by Fisher’s exact test with two-tailed \( p \) values. Statistical analyses of the genotype data were performed with GraphPad Prism software (San Diego, CA, USA) using 95% confidence intervals.

Results

Laminar and cellular localization of NUDR immunoreactivity and co-localization with 5-HT₁A receptor

The distribution of NUDR immunoreactivity was observed in cellular profiles in both prefrontal grey and white matter of PFC (BA 10). In the grey matter, immunoreactivity was spread across all cortical layers with the highest abundance in superficial layer II and upper layer III (Figure 2b). Double fluorescence immunostaining performed for NUDR and neuronal marker NeuN as well as for NUDR and astrocytic marker GFAP showed that the majority of NUDR-positive cortical cells represent neurons (Figure 3a). However, NUDR immunoreactivity was also observed in some glial cells expressing GFAP (Figure 3b). In neurons, NUDR was localized to nuclear and perinuclear areas, whereas in glia, NUDR immunoreactivity was restricted to the nuclear area. Co-labelling of NUDR and 5-HT₁A receptor revealed that most cortical cells expressing 5-HT₁A receptors also contain NUDR protein. NUDR immunoreactivity was localized mostly to the nuclear and perinuclear areas whereas 5-HT₁A receptor immunoreactivity was present in the cell body and neuronal processes (Figure 3c).

Protein levels of NUDR

Representative immunoblots of NUDR and β-actin protein from control and depressed subjects are shown in Figure 4a. The results of the Western blot analyses of NUDR protein in PFC (BA 10) of depressed and control subjects are summarized in Figure 5. The level of NUDR for each subject was determined as the ratio of the optical density of NUDR band to the optical density of the actin band. There was no significant difference between control and depressed subjects in the mean level of actin in both female (\( t_{12} = 0.49, p = 0.63 \)) and male (\( t_{11} = 0.49, p = 0.63 \)) groups. The mean protein level of NUDR in the PFC was significantly decreased by 42% in the female depressed group (\( 0.52 \pm 0.08, t_{12} = 2.64, p = 0.022 \)) compared to the matched female control group (\( 0.89 \pm 0.16, t_{12} = 2.64, p = 0.022 \)). Comparison of individual matched pairs revealed that the mean NUDR protein level was decreased in eight of the 13 depressed female subjects compared to the matched control subjects (Figure 5b). The mean NUDR protein level in the PFC of the male depressed subjects (\( 0.47 \pm 0.06, t_{12} = 3.33, p = 0.474 \)) was not significantly different from the matched male control subjects (\( 0.51 \pm 0.11, t_{12} = 0.39, p = 0.474 \)).
In contrast to the female subjects, only five of the 12 depressed male subjects had lower levels of NUDR protein compared to the matched control subjects (Figure 5d).

**Protein level of 5-HT₁A receptor**

Representative immunoblots of 5-HT₁A and β-actin protein from control and depressed subjects are shown in Figure 4b. The results of the Western blot analyses of 5-HT₁A protein in PFC (BA 10) of depressed and control subjects are summarized in Figure 6. The level of 5-HT₁A for each subject was determined as the ratio of the optical density of 5-HT₁A band to the optical density of the actin band. There was no significant difference between control and depressed subjects in the protein level of actin in both female (t₁₂ = 0.49, p = 0.63) and male (t₂₂ = 0.01, p = 0.99) groups. The mean protein level of the 5-HT₁A receptor in the PFC was significantly decreased by 46% in the female depressed group (0.31 ± 0.04, t₁₂ = 2.43, p = 0.030) relative to the matched female control group (0.42 ± 0.04, Figure 6c). Comparison of individual matched pairs showed that only five of the 12 depressed male subjects had lower levels of 5-HT₁A receptor protein compared to the matched control subjects (Figure 6d).

**Effects of covariates on NUDR and 5-HT₁A receptors**

The effect of the potential confounding variables such as age, PMI, brain pH, cause of death (suicide or non-suicide), onset of depression or duration of depression on protein levels of NUDR and 5-HT₁A receptor was evaluated in the female and male subject groups using the adjusted mixed-models test. There were no statistically significant differences in age, PMI and pH between female and male groups and there were no significant changes in the results after adjusting for age, PMI, brain pH as well as cause of death. There was a statistically significant difference between female and male MDD in the onset of depression (t₂₃ = 2.08, p = 0.048) and duration of depression (t₂₃ = 2.56, p = 0.017). However, there is no statistical evidence to support effects of these potentially confounding variables on changes in protein levels of NUDR and 5-HT₁A receptors related to depression.

---

**Figure 2.** Laminar and cellular localization of NUDR immunoreactivity in the human prefrontal cortical BA 10. (a) Nissl-stained section of a non-psychiatric control subject showing the typical cytoarchitectonic features of BA 10 (wide layer IV, in the centre of the cortical width, relatively narrow layer III). Image captured under the 2x objective. (b) Distribution of NUDR immunoreactivity in the same subject (adjacent section) to the one shown in (a). (c) Negative control showing the complete lack of NUDR immunoreactivity in the absence of primary antibody on the section adjacent to that shown in (b). Images (b) and (c) were captured under the 4x objective. (d) High power (40x objective) micrograph of NUDR immunoreactivity showing the presence of immunoreactive product in both neurons and glial cells.
C(-1019)G 5-HT$_{1A}$ promoter polymorphism with NUDR and 5-HT$_{1A}$ protein level

Since the 5-HT$_{1A}$ C(-1019)G polymorphism blocks regulation by NUDR of 5-HT$_{1A}$ receptor expression and has been associated with depression, the allele distribution in female and male control and depressed subjects was determined as shown in Table 2. No statistically significant difference in the allele or genotype frequency was observed, although the male cohort showed a trend for association of the G(-1019) allele with depression that was too small to reach statistical significance. These data suggest that decreased expression of 5-HT$_{1A}$ receptors observed in depressed female subjects is not associated with the G(-1019) genotype, and may result from decreased NUDR expression.

![Figure 3](image1.png)  
**Figure 3.** Co-localization of NUDR immunoreactivity in neurons and glia. (a) Co-labelling of NUDR immunoreactivity (green) with the neuronal marker NeuN (red). NUDR protein (yellow) is localized to neuronal nuclei and perinuclear areas. (b) Co-labelling of NUDR immunoreactivity (green) with the astrocytic marker GFAP (red). NUDR (yellow) is localized in glial nuclei. (c) Co-localization of NUDR immunoreactivity (green) and immunoreactivity for 5-HT$_{1A}$ receptor (red). NUDR immunoreactivity (yellow) is present in nuclei of majority of cells expressing 5-HT$_{1A}$ receptor immunoreactivity.

![Figure 4](image2.png)  
**Figure 4.** Representative Western blots showing the immunolabelling of (a) NUDR and β-actin, (b) 5-HT$_{1A}$ receptor and β-actin, in the prefrontal cortex of three pairs of control (Con) and matched major depressive disorder (MDD) subjects.
The present study found that the concentration of NUDR protein was significantly decreased in the PFC (BA 10) in female subjects with MDD relative to matched female control subjects, but was unchanged in the PFC (BA 10) of male depressed subjects compared to male controls. Furthermore, in the same cortical homogenates of the same female subjects with MDD, the protein levels of the 5-HT$_{1A}$ receptor were significantly reduced compared to the matched female controls, whereas male depressed subjects showed no change in 5-HT$_{1A}$ receptor protein levels in this cortical region. These findings represent the first examination in human post-mortem tissue of NUDR, a transcriptional repressor of the 5-HT$_{1A}$ receptor gene, in prefrontal cortical specimens of subjects with MDD.

But perhaps more importantly, our study documents a gender-specific alteration in both NUDR and 5-HT$_{1A}$ receptor protein expression in the PFC of female subjects diagnosed with MDD.

NUDR is the human homologue of Drosophila Deaf-1, which was identified as a DNA-binding protein and potential gene regulator (Huggenvik et al., 1998). The sequence and functional similarities between NUDR and Deaf-1 suggest that NUDR may also play a similar role in gene regulation. Indeed, recent evidence has shown that NUDR represses both human and rat 5-HT$_{1A}$ receptor promoter luciferase constructs. Furthermore, stable expression of NUDR significantly reduced the expression and binding of endogenous 5-HT$_{1A}$ receptors and mRNA levels in raphe cells, suggesting that NUDR negatively regulates both 5-HT$_{1A}$ receptor gene transcription and

**Figure 5.** NUDR protein levels in prefrontal cortex (PFC) of 13 female (a, b) and 12 male (c, d) control and major depressive disorder (MDD) subjects expressed as the mean ± S.E.M. of NUDR/actin relative optical density (ROD). Data were analysed using a maximum-likelihood mixed-models test. Female subject groups: control subjects (0.89 ± 0.16) compared to the matched MDD subjects (0.52 ± 0.08, $t_{12}=2.64, * p=0.022$). Male subject groups: control subjects (0.51 ± 0.11) compared to the matched MDD subjects (0.47 ± 0.06, $t_{10}=0.33, p=0.474$). NUDR levels in PFC of female (b) and male (d) MDD subjects expressed as percentage of values from paired control subjects.
protein expression (Lemonde et al., 2003). However, a very recent report from Czesak et al. (2006) revealed that NUDR (Deaf-1) has a dual function; it acts as a transcriptional repressor of the 5-HT$_{1A}$ receptor in serotonergic cells, but functions as a transcriptional enhancer of the 5-HT$_{1A}$ receptor in non-serotonergic cells such as post-synaptic neurons. Therefore, depending on the synaptic localization of 5-HT$_{1A}$ receptors, NUDR may serve distinct functional roles.

In our case, NUDR protein expression was decreased in PFC in depressed females. Therefore, if one assumes that NUDR is normally acting as a transcriptional enhancer in non-serotonergic, post-synaptic prefrontal cortical neurons, then the decrease in NUDR protein in the PFC may reduce its capacity to maintain or increase 5-HT$_{1A}$ receptor gene transcription and perhaps this contributes to the decrease in 5-HT$_{1A}$ receptors in the PFC of depressed female subjects.

It is important to note that our preliminary assessment of the regional and cellular localization of NUDR immunoreactivity in the human PFC was localized primarily to the superficial layers II and upper III. This laminar localization of NUDR is consistent with a previous report showing that the density of 5-HT$_{1A}$ receptor axon initial segment staining was highest in the superficial layers of BA 46 (Cruz et al., 2004). NUDR immunoreactivity was also found in both neurons and glia, and previous studies by Rajkowska and colleagues (1999) found that both of these cell types are diminished in density in the PFC of younger and older subjects with MDD. Further studies will be required to determine the specific cellular profiles that exhibit the decrease in NUDR protein expression in depressed female subjects.

Figure 6. 5-HT$_{1A}$ receptor levels in prefrontal cortex (PFC) of 13 female (a, b) and 12 male (c, d) control and major depressive disorder (MDD) subjects expressed as the mean ± S.E.M. of 5-HT$_{1A}$/actin relative optical density (ROD). Data were analysed using a maximum-likelihood mixed-models test. Female subject groups: control subjects (0.58 ± 0.09) compared to the matched MDD subjects (0.31 ± 0.04, $t_{12}$ = 2.43, * $p$ = 0.030). Male subject groups: control subjects (0.42 ± 0.04) compared to the matched MDD subjects (0.40 ± 0.04, $t_{11}$ = 0.39, $p$ = 0.702). 5-HT$_{1A}$ receptor levels in PFC of female (b) and male (d) MDD subjects expressed as percentage of values from paired control subjects.
depressed subjects: female, p = 0.6845. For allele frequency of control vs. depressed subjects: female, p = 1.0; male, p = 0.3801; all, p = 0.6645.

Our finding of a gender-specific decrease in 5-HT₁A receptor protein in female subjects with MDD has not previously been reported, but it is in general agreement with two PET imaging reports with one conducted in elderly depressed patients and the other study in postpartum depressed women. Meltzer and colleagues (2004) reported reduced 5-HT₁A receptor binding potential in the dorsal raphe nucleus and temporal limbic regions of elderly subjects with MDD. Although they did not find a significant gender difference perhaps due to their relatively small subject group, the majority of the depressed subjects were females. A more recent study by this same group found that 5-HT₁A receptor binding potential was significantly decreased in the mesiotemporal, subgenual cingulate and lateral orbitofrontal cortices of postpartum depressed subjects relative to postpartum control subjects (Moses-Kolko et al., 2008). The alterations in pre- and post-synaptic 5-HT₁A receptors in depressed women reveal specific serotonergic alterations and perhaps these alterations may contribute to the differential treatment response to antidepressant medications between genders (Baca et al., 2004; Kornstein et al., 2000, 2002). Our observation that 5-HT₁A receptor protein levels were unchanged in the depressed male subjects relative to matched controls is consistent with two previous studies that were composed of predominantly male subjects reporting no significant alterations in 5-HT₁A receptor binding sites (BA 10, Stockmeier et al., 1997) or in the density of 5-HT₁A receptor axon initial segments in the PFC of depressed subjects (Cruz et al., 2004).

It is unlikely that our main measures of NUDR and 5-HT₁A receptor protein levels were influenced by antidepressant medication since toxicology screens were negative for antidepressants for all depressed subjects. However, since several of the depressed subjects had a prescription for an antidepressant at the time of death, questions may be raised regarding the compliance of these patients and the possible long-term effects of antidepressants on these serotonin markers.

The 5-HT₁A receptor gene contains a novel C(-1019)G polymorphism and NUDR binds to the C(-1019) allele of the 5-HT₁A receptor and represses the transcription activity, but this binding does not occur with the G(-1019) allele (Albert and Lemonde, 2004; Lemonde et al., 2003). It was recently reported that the G(-1019) allele is two-fold more frequent in depressed subjects and four-fold enriched in completed suicide victims relative to matched control subjects (Lemonde et al., 2003). Moreover, the G(-1019) allele of the 5-HT₁A receptor gene is associated with reduced therapeutic response to antidepressant treatment and this effect is more pronounced in female than in male subjects (Lemonde et al., 2004). In a previous study, significant association of the G(-1019) allele with suicide was observed with a larger cohort of male subjects (Lemonde et al., 2003). Interestingly, our male cohort of depressed suicides also showed a trend for association with depression. The finding that the female subjects did not display an association with the G(-1019) allele is important, because it implies that the decrease in 5-HT₁A receptors observed in these subjects is not explained by impaired repression by NUDR at the G allele. Rather, the association of decreased NUDR and 5-HT₁A receptor expression levels in depressed females suggests a causal link between dysregulation of NUDR expression leading to decreased 5-HT₁A receptor expression in cortex. This is consistent with the finding that NUDR activates receptor expression in non-serotonergic neurons that express post-synaptic 5-HT₁A receptors; hence a decrease in NUDR would be expected to down-regulate post-synaptic receptor expression. The basis for decreased NUDR protein in depressed female subjects remains unclear as little is known of factors that regulate NUDR expression.

The specific reduction in both NUDR and 5-HT₁A receptor expression in the PFC of depressed female subjects raises questions regarding the underlying biological mechanisms associated with these changes in women with MDD. The ovarian steroid hormones, oestrogen and progesterone are biological factors that warrant consideration in this regard. Although

<table>
<thead>
<tr>
<th>Subject</th>
<th>n</th>
<th>C/C</th>
<th>C/G</th>
<th>G/G</th>
<th>Allele C</th>
<th>Allele G</th>
</tr>
</thead>
<tbody>
<tr>
<td>Female</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>13</td>
<td>4</td>
<td>7</td>
<td>2</td>
<td>15</td>
<td>11</td>
</tr>
<tr>
<td>Depressed</td>
<td>13</td>
<td>5</td>
<td>6</td>
<td>2</td>
<td>16</td>
<td>10</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control</td>
<td>12</td>
<td>6</td>
<td>4</td>
<td>2</td>
<td>16</td>
<td>8</td>
</tr>
<tr>
<td>Depressed</td>
<td>12</td>
<td>3</td>
<td>6</td>
<td>3</td>
<td>12</td>
<td>12</td>
</tr>
</tbody>
</table>

The 5-HT₁A C(-1019)G allele distribution in control and depressed subjects.

Genotype frequencies were analysed using a two-tailed χ² test and allele frequencies were analysed using a two-tailed Fisher’s exact test. For genotype frequency of control vs. depressed subjects: female subject group (χ² = 0.1880, d.f. = 2, p = 0.9103); male subject group (χ² = 0.600, d.f. = 2, p = 0.4493); all (χ² = 0.3768, d.f. = 2, p = 0.8283). For allele frequency of control vs. depressed subjects: female, p = 1.0; male, p = 0.3801; all, p = 0.6645.

Table 2. 5-HT₁A C(-1019)G allele distribution in control and depressed subjects.
Currently there are no available data on the effects of oestrogen or progesterone on NUDR, there is substantial evidence to support a role for oestrogen in regulating the serotonin system and 5-HT_1A receptors specifically. Studies of oestrogen treatment in rodents have yielded inconsistent results with increased (Flugge et al., 1999), decreased (Osterlund et al., 2000), or unchanged (Clarke and Maayani, 1990; Frankfurt et al., 1994) post-synaptic 5-HT_1A binding sites. On the other hand, ovariectomized non-human primates that were subsequently treated with oestrogen or oestradiol plus progesterone show a significant reduction in 5-HT_1A autoreceptor binding sites, mRNA and basal and stimulated [³⁵S]GTP·γ·S binding in the dorsal raphe nucleus and decreased post-synaptic 5-HT_1A receptor binding sites in the hypothalamus (Lu and Bethea, 2002). Thus, oestrogen treatment appears to modulate 5-HT_1A receptor expression in distinct brain regions. Regarding the female subjects in our study, we have no evidence from either toxicology screens or from the structured interviews that any of the female subjects were receiving hormone therapy at the time of death. Moreover, the majority of the female subjects were aged >45 yr (20/26), and only six of the females were aged <45 yr. Therefore, most of the female subjects were probably perimenopausal or post-menopausal. Taken together, these characteristics suggest that circulating oestrogen did not have a confounding effect on 5-HT_1A receptor expression in our female subjects. However, this evidence does not exclude the possibility that ovarian hormones may play a role in the underlying mechanisms associated with the reduction in NUDR and 5-HT_1A receptors in depressed women. Clearly, further studies are required to understand the biochemical interactions between oestrogen, NUDR and 5-HT_1A receptors and their role in the pathophysiology of MDD.

In summary, this report presents evidence of diminished protein expression of NUDR, a novel transcription factor, and of 5-HT_1A receptors, the target protein regulated by NUDR, in the PFC of female subjects with MDD. It is intriguing to speculate that alterations in NUDR in depressed women may contribute to altered serotonin neurotransmission and thereby constitute one biological mechanism that may contribute to the greater incidence of depression in women.

Acknowledgements

We acknowledge Dr Javier Miguel-Hildalgo for assistance in using the confocal microscope to generate the immunofluorescent photomicrographs and Tarsha Harris for technical assistance in punching tissue samples and preparation of proteins for assays. The assistance of Bryan Roth, M.D., Ph.D., in four of the psychiatric assessments is gratefully acknowledged. We are deeply appreciative of the assistance of the next-of-kin of the deceased and gratefully acknowledge the assistance of the Cuyahoga County Coroner’s Office, Cleveland, OH, USA. This study was supported by grants from the National Institute of Mental Health: MH63187, MH67996, MH61578, MH60451; National Center for Research Resources: RR17701 and the Canadian Institutes of Health Research.

Statement of Interest

G. Rajkowska is a consultant for Eli Lilly and Company.

References


Clarke WP, Maayani S (1990). Estrogen effects on 5-HT1A receptors in hippocampal membranes from...
NUDR and 5-HT\textsubscript{1A} receptors in PFC of MDD subjects

Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, Kawanishi Y, Harada S, Tachikawa H, Okubo T, Shiraishi


Sargent PA, Kjaer KH, Bench CJ, Rabiner EA, Messa C, Meyer J, Gunn RN, Grasby PM, Cowen PJ (2000). Brain serotonin1A receptor binding measured by positron emission tomography with [\textsuperscript{11}C]WAY-100635: effects of...
depression and antidepressant treatment. *Archives General Psychiatry* 57, 174–180.


